These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
26. Thrombolytic therapy for acute myocardial infarction in the elderly. Straznicky IT; White HD Coron Artery Dis; 2000 Jun; 11(4):299-304. PubMed ID: 10860172 [No Abstract] [Full Text] [Related]
27. Thrombolytic therapy of myocardial infarction--it's time for science, not marketing: the perspective of a practicing cardiologist. Vogel JH Clin Cardiol; 1991 Jul; 14(7):548. PubMed ID: 1810292 [No Abstract] [Full Text] [Related]
28. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?]. Negrini M G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921 [No Abstract] [Full Text] [Related]
29. Thrombolytic therapy for acute myocardial infarction. Are inclusion criteria too stringent? Handlin LR; Vacek JL Postgrad Med; 1994 Mar; 95(4):77-82. PubMed ID: 8121861 [TBL] [Abstract][Full Text] [Related]
31. [My practice of thrombolysis in the acute phase of myocardial infarction in the light of extensive studies]. Bory M Ann Cardiol Angeiol (Paris); 1992 Dec; 41(10):595-7. PubMed ID: 1300923 [TBL] [Abstract][Full Text] [Related]
32. [Thrombolytic therapy for myocardial infarction in oral anticoagulation]. Pizzulli L; Lüderitz B Dtsch Med Wochenschr; 1996 Mar; 121(13):424. PubMed ID: 8681737 [No Abstract] [Full Text] [Related]
34. Variable depletion of endogenous factor XII-dependent fibrinolytic activity following thrombolytic therapy of myocardial infarction and its relation to reinfarction. Kluft C; Munkvad S; Gram J; Jespersen J Agents Actions Suppl; 1992; 38 ( Pt 2)():299-304. PubMed ID: 1462835 [No Abstract] [Full Text] [Related]
35. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Kalish SC; Gurwitz JH; Krumholz HM; Avorn J J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123 [TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Woo KS; White HD Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049 [TBL] [Abstract][Full Text] [Related]
37. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748 [TBL] [Abstract][Full Text] [Related]
38. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Califf RM; Stump D; Topol EJ; Mark DB Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606 [No Abstract] [Full Text] [Related]
39. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. Sherry S; Marder VJ J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964 [TBL] [Abstract][Full Text] [Related]
40. Clinical trials and decisions for thrombolytic therapy in patients with acute myocardial infarction. Conti CR Clin Cardiol; 1990 May; 13(5):307-8. PubMed ID: 2112073 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]